Loss-of-function mutations in EPHA4 results in significantly longer survival of ALS patients and pharmacological inhibition of EPHA4 signaling has demonstrated to improve functional performance and motor neuron survival in ALS animal models (Van Hoecke et al., 2012; Rué et al., 2019). This evidence concerns the gene EPHA4 and amyotrophic lateral sclerosis.